Xu YH, Yu M, Wei H, Yao S, Chen SY, Zhu XL, Li YF. Fibroblast growth factor 22 is a novel modulator of depression through interleukin-1β.
CNS Neurosci Ther 2017;
23:907-916. [PMID:
28948716 DOI:
10.1111/cns.12760]
[Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2017] [Revised: 09/05/2017] [Accepted: 09/07/2017] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND AND AIMS
Emerging evidence shows that fibroblast growth factor 22 (FGF22) plays a critical role in the etiology of depression. However, the molecular mechanisms of FGF22 are not fully comprehended. Here, the effect of FGF22 in depression and its relationship with interleukin-1β (IL-1β) were investigated in clinical, animal, and cell experiments.
METHODS
Serum from depressive patients was collected, and the levels of FGF22 and IL-1β were analyzed by ELISA. The chronic unpredictable mild stress (CUMS) model was established, and primary hippocampal neuronal cells were cultured to examine changes in FGF22 and IL-1β levels in rat hippocampus.
RESULTS
The results revealed a negative correlation between serum FGF22 levels and serum IL-1β levels. The expression of IL-1β in the CUMS rat hippocampus decreased, and the apoptosis of hippocampal cells improved after the injection of lentiviral vector-mediated FGF22 (LV-FGF22). Further tests in primary hippocampal neuronal cells also showed a reduction in IL-1β and the cell apoptosis rate after treatment with FGF22.
CONCLUSION
In conclusion, the results revealed that FGF22 plays a role in alleviating depression, which may be mediated by reduced expression of IL-1β.
Collapse